Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
Clin Infect Dis
; 39 Suppl 5: S248-57, 2004 Nov 01.
Article
en En
| MEDLINE
| ID: mdl-15494896
ABSTRACT
Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%-0.7% of isolates) during this period. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome. Although drug-resistant HSV is more commonly isolated from immunocompromised patients (4%-7% of isolates) and is more likely to be clinically significant, the prevalence of drug-resistant HSV even among these patients, has been stable over the past 2 decades. Despite this stable prevalence, disease due to drug-resistant HSV remains an important problem for many immunocompromised patients, including those with HIV infection. This article reviews the prevalence, pathogenesis, and implications of drug-resistant HSV infections in HIV-infected patients.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Infecciones por VIH
/
Simplexvirus
/
Herpes Simple
/
Nucleósidos
Tipo de estudio:
Risk_factors_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Clin Infect Dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2004
Tipo del documento:
Article
País de afiliación:
Estados Unidos